Beta Drugs Ltd

NSE: BETA · BSE: 531481 · Pharmaceuticals & Biotechnology · 27 announcements

Share price: ₹1,991.00
Market cap: ₹2,207 Cr
Revenue (annual): ₹384.8 Cr
Net profit (annual): ₹41.48 Cr
P/E (TTM): 48.4×Sector 47.4×
Promoter holding: 59.10%-5.53% QoQ
FII holding: 1.02%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

27 Jul 2026 21:24 IST NSE

Beta Drugs Investor Presentation: Key Takeaways

Beta Drugs Ltd. reports Q1-FY27 revenue of INR 1,255 Mn with 21.83% EBITDA margin. Diversifying beyond core oncology into IVF via Nivian acquisition.

Call: Guides 15% growth

Open call summary → Read the filing ↗

22 May 2026 20:26 IST NSE

Earnings Call

Beta Drugs Earnings Call: Key Takeaways

Beta Drugs delivered record EBITDA but missed revenue guidance due to delayed export tenders and strategic withdrawal from the low-margin Platin segment.

Open call summary → Read the filing ↗

15 May 2026 08:41 IST NSE

Earnings Call

Beta Drugs Earnings Call: Key Takeaways

Beta Drugs delivered FY26 revenue of ₹385 Cr with a shift towards high-margin branded oncology (36% of mix) and 22.57% EBITDA margin.

Open call summary → Read the filing ↗